Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Primary result · Cohort 1 (prior tirzepatide): % of body weight reduction maintainedResult — go to the resultEstimated treatment difference 25.5 % 95% CI 14.5–36.5Authors' conclusion
These data demonstrate orforglipron's potential as a globally scalable option for minimizing weight changes after injectable therapy.
Study context
- Population
- Participants previously treated with tirzepatide (cohort 1: N = 205) or semaglutide (cohort 2: N = 171) in the SURMOUNT-5 study2 cohorts
- Comparison
- Once-daily oral orforglipron vs placebo after tirzepatide or semaglutide
- Primary endpoint
- Maintenance of body weight reduction (MBE % of body weight reduction maintained) in participants who achieved body weight plateau
- Follow-up
- Week 52
Methodological detailsdouble-blind, placebo-controlled, phase 3b, Limitations: no comparator arm continuing injectable obesity-management medications; 1-year duration
- Double-blind
- Placebo-controlled
- Phase 3b
- Limitations: no comparator arm continuing injectable obesity-management medications; 1-year duration
Primary result
As reported in the abstract
Cohort 1 (prior tirzepatide): % of body weight reduction maintained
Estimated treatment difference
25.5 %
95% CI 14.5–36.5
P < 0.001
By group
Orforglipronvs Placebo
estimated treatment difference 25.5 % (95% CI 14.5–36.5); P < 0.001
Secondary outcomes
Model-based estimate (MBE)
| Outcome | Orforglipron | Placebo | Estimated treatment difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Cohort 2 (prior semaglutide): % of body weight reduction maintained · week 52Treatment-regimen estimand | 79.3% (SE 4.42) | 37.6% (SE 7.46) | 41.7 (24.4–59.0) | P < 0.001 | |
| −50050100Difference (linear scale) |
Key secondary endpoints
- All key secondary endpoints were met
Safety
Adverse events
- Most common AEs were gastrointestinal, mostly mild to moderate
Original publication
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. Published 13 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →